Questions about COVID-19?

For information about what AbbVie is doing to address the global COVID-19 crisis, please click here

Unavailable Data

AbbVie has not studied the use of SKYRIZI in patients with COVID-19.

At this time, the safety and efficacy of the authorized COVID-19 vaccines have not been established in immunocompromised persons, persons with autoimmune conditions or persons who take immunosuppressive medications or therapies¹ such as SKYRIZI.

Each patient’s unique clinical circumstances should be considered when managing their SKYRIZI therapy and when deciding if a vaccine is appropriate for them.

Select Information about Infections and Immunizations from the Prescribing Information²

Infections

SKYRIZI may increase the risk of infection. Treatment with SKYRIZI should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, monitor the patient closely and do not administer SKYRIZI until the infection resolves.

Immunizations

Prior to initiating therapy with SKYRIZI, consider completion of all age appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with SKYRIZI. No data are available on the response to live or inactive vaccines.

Please see additional Important Safety Information for SKYRIZI below.

Please refer to the full SKYRIZI Prescribing Information for additional information.

Staying Current

Due to the rapidly evolving situation, interim guidance disseminated by government public health agencies and Dermatology professional medical societies such as the International Psoriasis Council and National Psoriasis Foundation on disease management and COVID-19, including authorized vaccines, is being updated frequently and should be checked often.

References: 1. Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States. https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html. Accessed January 6, 2021. 2. SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc